The synthetic compound 2-{difluoromethyl)-d/-ornithine irreversibly inhibits ornithine decarboxylase and reduces the intracellular levels of the polyamine cell cycle factors putrescine and spermidine. The drug has shown chemopreventive efficacy in numerous laboratory epithelial cancer models and is a prototype for antiproliferative agents. Chronic toxicity studies in rats and dogs were performed to characterize the toxicities of the compound at high dosages and to support its further development in clinical trials as a potential chemopreventive agent. Chronic administration (52 weeks) by gavage to Charles River CD rats at dosages of 400, 800, and 1600 mg/kg produced weight loss, increased platelets, alopecia and skin abrasions, dermatitis, liver necrosis, and gastric inflammation. The no-effect dose in this study was considered 400 mg/kg. Chronic administration by capsule to dogs at dosages of 50, 100, and 200 mg/kg produced conjunctivitis, hyperkeratosis and alopecia, and cystic intestinal crypts. A no-effect dose was not determined in this study. The toxicities demonstrated in these studies may be minimized at lower dosages and support the further development of this compound in chemopreventive clinical investigations. C 1994 Society of Toxicology.
The preinvasive stage of epithelial cancer is described as "intraepithelial neoplasia" and is characterized in its proliferative phase by the morphological criteria of increased mitoses, abnormal mitoses, and disordered maturation (Boone et ai, 1992) . The arrest, suppression, or elimination of the proliferative phase of intraepithelial neoplasia, prior to its invasion through the basement membrane as cancer, provides one of several mechanistic opportunities for chemopreventive drug development.
Among the molecular requirements of rapidly proliferating cells are the polyamines putrescine, spermidine, and spermine. Experimental evidence suggests that polyamines are important to the G1 and S phases of the cell cycle, proba-bly as nucleotide precursors (Luk and Casero, 1987) . Inhibitors of polyamine biosynthesis and especially of the rate-limiting enzyme ornithine decarboxylase (ODC, EC 4.1.1.17), which converts ornithine to putrescine, can inhibit cell proliferation (McCann et ai, 1992) . 2-(Difluoromethyl)-^/-ornithine (DFMO) is an enzyme-activated, irreversible inhibitor of ODC; the inhibition of ODC decreases intracellular levels of putrescine and spermidine and decreases in vitro cell growth and in vivo tumor growth (Pegg, 1988) .
The compound was developed for the treatment of Trypanosoma brucei gambiense, which causes African sleeping sickness (Webster, 1990) ; DFMO not only suppresses trypanosome DNA synthesis but also has apparent unique effects in trypanosomes (McCann et ai, 1992) . In several mammalian in vivo tests for chemopreventive efficacy, in conjunction with the administration of model carcinogens, DFMO significantly reduced tumor incidences (Boone et al., 1990; Ratko#a/., 1990) . Chemopreventive activity has been shown in mouse skin (Weeks et al., 1982; Takigawa et al., 1983; Verma et ai, 1986) ; mouse (Kingsnorth et ai, 1983) and rat (Nigro et al., 1986; Reddy et al., 1990; Rao et ai, 1991) colon; mouse (Ratko et al., 1990) and rat (Homma et al., 1987) urinary bladder, and rat mammary gland (Thompson and Ronan, 1986) .
Chronic one-year toxicity studies in rats and dogs were performed to characterize the potential toxicities of DFMO at high dosages and to support its potential further development as an antiproliferative, chemopreventive agent in clinical trials (Goldenthal, 1990) . The results of these studies are the subject of this report.
MATERIALS AND METHODS
Clinical pathology. Blood samples from the rats were collected from the orbital sinus following an overnight fast in which the animals had free access to water. From the dogs, blood samples were collected from the jugular vein following an overnight fast in which food and water were removed. Urine was collected during the fasting periods.
Hematology measurements of leukocyte, erythrocyte, and platelet counts, hematocrit, hemoglobin, mean corpuscular volume (MCV), mean corpuscular hemoglobin concentration (MCHQ, and mean corpuscular hemoglobin (MCH) were performed on whole blood using an Ortho ELT-8 analyzer. Leukocyte differentials and reticulocyte counts were determined from blood smears by light microscopy. Prothrorabin time was measured on plasma using a MLA Electra 800 analyzer.
Biochemical measurements for sodium, potassium, and chloride were performed on serum using a Beckman E4A Electrolyte analyzer. Alanine and aspartate aminotransferases, alkaline phosphatase, urea nitrogen, creatinine, calcium, total protein, total bilirubin, albumin, cholesterol, and glucose were measured in serum on a Coulter DACOS analyzer.
Urinalysis measurements included volume, color and appearance, and, by refractometry, specific gravity. Protein, pH, glucose, ketones, urobilinogen, nitrites, bilirubin, leukocytes, and occult blood were measured on a Miles CliniTek 200. Microscopic examination of the spun sediment was performed by light microscopy.
Anatomic pathology. A complete necropsy was performed on all animals. The following organs were weighed: adrenals, brain, heart, kidneys, liver, ovaries, and testes. In addition, the pituitary, spleen, and thyroid/ parathyroid from the dogs were weighed. Organ-to-body weight and organto-brain weight ratios were calculated. The following organs and tissues were collected into phosphate-buffered neutral formalin: adrenal (two), aorta, bone with marrow (femur), brain (three levels), diaphragm, eye with optic nerve, gastrointestinal tract (nine tissues), gonads (ovaries or testes with epididymis), heart, kidneys, liver (three sections), lung with mainstem bronchi, lymph nodes (mandibular and mesenteric), mammary region (females), pancreas, pituitary, prostate and seminal vesicles, salivary gland (mandibular), sciatic nerve, skeletal muscle (thigh), skin, spinal cord (thoracolumbar), spleen, thymic region, thyroid/parathyroid, trachea, urinary bladder, uterus, gross lesions, and tissue masses. Paraffin sections were stained with hematoxylin-eosin and examined microscopically. All tissues from the dogs were prepared and examined; in the rat study the control and high-dose group tissues and identified low-and mid-dose target tissues were prepared and examined. Lesions were graded for severity as trace, mild, moderate, or severe.
Statistics. Body weights, food consumption, clinical pathology, and organ weights and organ ratios were analyzed using one-way ANOVA and Bartlett's test for homogeneity of variance. Treatment groups were compared to control by sex using a t test (adjusted for equal or unequal variance) (Steel and Torrie, 1960; Ostle, 1954 ). Dunnett's multiple comparison tables or pairwise comparisons with a Bonferroni correction were used to determine significance (Dunnett, 1964) . Nonparametric analyses were conducted as appropriate by transforming the data into ranks prior to analysis (Conover and Iman, 1981) . The levels of significance were p < 0.05 and 0.01.
RESULTS

Mortality.
No deaths attributed directly to drug toxicity occurred during either study. Survival was similar in the rat study across the groups. One, four, six, and four females and one, two, four, and zero males died or were terminated in extremis in the 0, 400, 800, and 1600 mg/kg groups, respectively. All dogs survived to the scheduled termination.
Observations. Administration of DFMO by gavage to rats caused dermatological reactions. Within the first 13 weeks and in the 1600 mg/kg group, mild to moderate alopecia and scabs were noted primarily on the head and lips, respectively. The distribution generalized and the incidence increased over time, especially among the females in the 1600 mg/kg group. In the 800 mg/kg group the incidence was less than that in the 1600 mg/kg group and the females were more affected than the males, in whom the onset was also delayed until about Week 27. Alopecia was either generalized in distribution or localized in different parts of the body, such as ventral thorax, abdomen, posterior dorsal region, perinasal area, and eyelid. Abrasion or scab was Note. Alopecia and abrasions of the skin and eyelid were macroscopic observations. Dermatitis, liver necrosis, and stomach inflammation were microscopic observations. All group A' = 25. Observations were made at death or termination.
noted on lip, head, nasal or perinasal area, shoulder, neck, rats from Week 2 and for the females from Week 10 onaxilla, dorsal thorax, ear, and eyelid. Dermatological effects ward. The percentage difference from the control group at were not seen at 400 mg/kg and 0 mg/kg. Cumulative inci-Week 52 was -26.4% for the males and -23.0% for the dences are presented in Table 1. females. Body weights were not statistically significantly Dermatological reactions were also caused in dogs by the lower at Week 52 in the other groups (-4.6 and +1.5% in administration of DFMO. Alopecia, dermatitis around the the male and -6.1 and -2.1% in the female, 800 and 400 eyes, ears, and neck, and ocular discharge with mild to mod-mg/kg groups, respectively). Food consumption, expressed erate thickening of the conjunctiva were observed in a dose-as average mean grams consumed/animal/day, through related manner for all of the treated dosage levels through-Week 52 was slightly lower in the 1600 mg/kg group than out most of the study. The alopecia was more severe in the that in the control group (-5.7% males and -3.5% females, 100 and 200 mg/kg groups and was present throughout the respectively). Statistically significant decreases in food conbody. The ocular discharge was initially observed at Week 6 sumption (p < 0.05 and p < 0.01) were measured through of the study and the alopecia was first observed during Week 14 in the 1600 mg/kg males and through Week 15 in Week 17. Injection of the sclera was observed for the treated the females; thereafter, given the lower body weights of this animals in a dose-related manner. In addition, diarrhea and treated group, the food consumption when expressed as soft stool were seen more often in the treated than in the grams consumed/kg/day was significantly increased (/? < control dogs throughout the study. Cumulative incidences 0.01) over the control group. Statistically significant inare presented in Table 2 .
creases in food consumption (as g/kg/day) were also noted Weight gain was decreased as an effect of treatment in the for the lower dose groups, more so in the 800 mg/kg group, rat study (Table 3) . Mean body weights were statistically Dog body weights were lowered in relation to dose by significantly decreased (p < 0.01) for the 1600 mg/kg male treatment with DFMO when compared to control ( Note. Alopecia and thickened conjunctiva was macroscopic observations. Conjunctivitis, skin hyperkeratosis, and duodenal cystic crypts were microscopic observations. All group N -4. 4). The percentage difference from the control group at 100 mg/kg and in two at 200 mg/kg. At 6 months mucoid Week 52 was -20.3, -9.8, and -4.5% for the males and conjunctivitis was identified in all eight dogs at 200 mg/kg, -6.3, -7.1, and +1.8% for the females receiving 200, 100, seven at 100 mg/kg, three at 50 mg/kg, and one in the conand 50 mg/kg, respectively; however, these differences were trol. Lacrimal production was within normal limits. At 9 not statistically significant. Males at 100 and 200 mg/kg months the conjunctivitis in the control dogs was resolved had lower body weights throughout the study with statisti-but the treated dogs still had the condition and, in addition, cal significance noted for the 200 mg/kg group at Weeks had increased alopecia around the eyelids and an obvious 8-11 and 21-23 when compared to the control group. Fe-hypersecretion of the skin mucoid glands. There was ademales at 100 and 200 mg/kg had lower body weights quate tear film to protect the cornea from disease and bactethroughout the study although no statistical significance rial cultures did not identify a bacterial cause for the muwas observed. The 50 mg/kg groups had body weights com-coid conjunctivitis. At 12 months one 50 mg/kg dog still parable to those of the control group. Food consumption, demonstrated a mild mucoid conjunctivitis and the 100 expressed as g/animal/day, was decreased for the 200 mg/ and 200 mg/kg groups were the same as those at 9 months, kg males (-23.3% less than control through Week 52), with Two males at 50 mg/kg and two females at 100 mg/kg also statistically significant decreases noted primarily within the had residual trace conjunctivitis seen microscopically. The first 9 weeks. Among the 50 and 100 mg/kg males, food changes and distribution indicated a test article-related paconsumption was lower than control during the first 30 thology. weeks of the study and then greater than control thereafter.
Electrocardiographic examinations of the dogs were Food consumption among the treated female groups was normal. greater than that of the control.
Clinical pathology. Among the hematology measureNo ophthalmological changes related to treatment were ments in rats (Table 5) , the platelet count was the most seen in the rats. However, ophthalmological changes oc-affected. Platelets were increased approximately 50% in the curred among the dogs treated with DFMO. Slight to mod-1600 mg/kg group males and females starting at Month 3 erate conjunctivitis was present at 3 months in three dogs at and in the 800 mg/kg males starting at Month 6 (the effect • p < 0.05 compared to control. " p < 0.01 compared to control.
was smaller in the females). Other effects of treatment included statistically significant but biologically slight decreases in the 1600 mg/kg female hemoglobin, MCV, MCH, & MCHC; in the 1600 mg/kg males these values were also slightly decreased and were occasionally statistically significant. Leukocyte and lymphocyte counts in males and females were slightly increased in a dose-response manner and were occasionally significant at 800 and 1600 mg/kg.
No increases in platelet number were measured among the dogs treated with DFMO (Table 6 ). Statistically significant changes were noted among various hematological parameters; however, the magnitude of the changes was not biologically meaningful. Erythrocyte, hemoglobin, and hematocrit values were nonsignificantly slightly reduced (approximately 10-15%) at 3 and 6 months only in the 200 mg/kg males. Prothrombin time was statistically significantly slightly increased (< 1 sec) in the 100 and 200 mg/kg males, and segmented neutrophils were nonsignificantly slightly increased in the treated groups. Significantly but biologically slightly reduced MCH and MCHC were seen in the 200 mg/kg females but the measured erythroid parameters were normal.
No biologically significant effects of treatment on clinical chemistry parameters were identified in the rats. Alkaline phosphatase was slightly decreased across dosages and sev- eral values were statistically significant. Glucose was slightly but statistically significantly decreased below control in the 1600 mg/kg group. Other individual elevations were noted for the transferases among the 1600 mg/kg males.
No clinical chemistry parameters in the dogs were biologically significantly affected by treatment with DFMO, although occasional statistical significances were identified. Slight, but dose-related, decreases in total protein and cholesterol were seen in both sexes.
There was a slight decrease in rat urinary pH values at all intervals of analyses in the 1600 mg/kg group. Other parameters were similar to those of the control group. No urinalysis parameters were affected by DFMO treatment in the dog study.
Anatomic pathology. There were no DFMO-related, group mean organ weight changes distinguishable from secondary influences of body weight change in the rat study (Table 3 ). The 800 mg/kg male kidney weight increase is probably repeatable and not based on the body weight effect. The statistically significant absolute liver weight decreases in the 1600 mg/kg groups may be correlated to microscopic changes seen in the livers of the male rats from the 800 and 1600 mg/kg groups, as described below.
In the dog study (Table 4) , the few statistically significant organ weight differences which occurred in the treated groups were considered to be biological variations or reflections of lower body weight. No DFMO-induced organ weight changes were considered to have resulted from chronic administration.
Microscopic changes were observed in tissues from the 800 and 1600 mg/kg dosage group rats of both sexes (Table  1) . The major changes consisted of chronic or necrotic dermatitis, an increased incidence of liver necrosis in male rats from the 800 and 1600 mg/kg dosage groups, and inflammation in the glandular portion of the stomach of male rats from the 800 and 1600 mg/kg dosage groups. The chronic dermatitis (not tabulated in Table 1 ) was characterized by acanthosis and hyperkeratosis of the epidermis and by infiltration of the dermis, chiefly by macrophage and lymphocyte inflammatory cells. Some proliferation of dermal fibroblasts and downgrowth of retepegs were also observed. This condition was seen in five females at 800 mg/kg and in three females at 1600 mg/kg and was trace to mild in severity. Moderately severe chronic dermatitis was observed in one 1600 mg/kg group male. In the more advanced cases of necrotic dermatitis, tabulated in Table 1 and illustrated in Fig. 1 , there was necrosis of the epidermis and adjacent dermis. Males in the higher dosage groups showed instances of coagulative necrosis of the liver, which was mild in severity (Fig. 2) . The lesion was characterized by a loss of normal cellular outlines and by an eosinophilic, structureless appearance with inflammatory reaction or hemorrhage around the necrotic area. The focal coagulative necrosis could be due to capillary thrombosis secondary to thrombocytosis and could be of such an age that elevated liver enzymes would not be detected. Finally, the stomach inflammation was trace or mild in severity and involved primarily the submucosa. In addition, several skin abscesses were noted: two were mildly severe in the 1600 mg/kg males, one mild one moderate in severity in both the 800 and 1600 mg/kg females, and one moderately severe eyelid abscess in both a 1600 mg/kg male and female. Two granulomas of mild severity occurred in the 1600 mg/kg females. In the dog study the microscopic changes related to treatment with DFMO included conjunctivitis, hyperkeratosis and alopecia, and cystic intestinal crypts ( Table 2 ). The chronic inflammatory changes in the palpebral conjunctiva were characterized by mononuclear infiltrations; however, no morphological changes were observed in epithelium lining the conjunctiva (Fig. 3) . Mild hyperkeratosis was observed in the skin in all treated groups. The associated alopecia, however, did not involve changes in the hair follicles and adnexa. Finally, in all treated groups a higher than normal incidence of cystic crypts, containing cellular debris, were observed to be distributed along the intestine, particularly in the duodenum but also in the jejunum, cecum, and colon (Fig. 4) .
DISCUSSION
Chronic administration of DFMO by gavage to Charles River CD rats at dosages of 400, 800, and 1600 mg/kg produced toxicological effects. Cumulative body weight gain was 26.4% lower than control in the 1600 mg/kg group males and 23.0% lower in the females. This effect was related to decreased food consumption. The 1600 mg/kg group consumed 4 to 6% less g/animal/day than control through Week 52 and the decreased food consumption was statistically significant during the first 15 weeks of the study when the animals were in their most rapid growth phase. Inhibition of weight gain at high DFMO dosages has been documented and distinguished from efficacy in the rat mammary tumor model (Thompson et ai, 1984) . Among the clinical pathology measurements, the total platelet counts were increased above control approximately 50% in the 1600 mg/kg males and females and in the 800 mg/kg males; the increase was less in the 800 mg/kg females. This thrombocytosis was most likely part of a reactive response to the inflammatory histological changes in the skin, liver, and stomach. Urinary pH was slightly lower than control in the 1600 mg/kg group, which is consistent with the fact that absorbed DFMO hydrochloride is known to be eliminated without metabolism in the urine. Dermatological changes consisting of alopecia and skin abrasions or scabs occurred in the 800 and 1600 mg/kg groups; the severity of the lesions was considered mild to moderate. Histopathological changes included chronic and necrotic dermatitis in the 800 and 1600 mg/kg groups. The severity of the dermatitis was mild to moderate. In addition, necrosis of the liver and inflammation in the glandular portion of the stomach was observed in the male rats, primarily at the 800 and 1600 mg/kg dosage levels. The liver and stomach lesions were considered trace to mild in severity. The mechanisms by which DFMO caused these changes probably involved several factors. Administration of DFMO itself may have contributed to gastric irritation and inflammation. Certainly malnutrition and possibly inhibition of cell division and growth by DFMO also contributed to the observed effects, although cellular replication rate measurements were not performed in these studies. Alopecia and dermatitis are known to result from malnutrition and vitamin deficiencies. Similarly, malnutrition and cell cycle inhibition probably contributed to liver necrosis; DFMO is not metabolized to a reactive form by the liver. The no observed effect level in this study was 400 mg/kg. Chronic administration of DFMO by capsules to dogs at dosages of 50, 100, and 200 mg/kg produced toxicological effects. Alopecia; dermatitis around the eyes, ears, and neck; and mucoid conjunctivitis were observed in a doserelated manner. Body weight was decreased below control in relation to dose and was 20.3% lower in the 200 mg/kg males, although the individual variation blocked statistical significance. The 200 mg/kg males also consumed 23.3% less grams of food per animal than the controls during the study. No biologically significant clinical pathology changes resulted from DFMO treatment. Histopathology changes included conjunctivitis, hyperkeratosis and alopecia, and cystic intestinal crypts. As in the rat study, these effects were most likely caused by malnutrition and cell cycle inhibition. Hyperkeratosis and alopecia result from malnutrition. Tissues such as the intestinal crypts where cell division is continual are susceptible to the antiproliferative effect of DFMO; decreased thymidine labeling has been measured in rat colon (Reddy el ai, 1990) . However, the cause of the mucoid conjunctivitis was not apparent. No significant primary changes in the conjunctival lining epithelium were seen. Lacrimal production was normal, although there was hypersecretion of the skin mucoid glands. No bacterial cause could be identified. Due to this condition, a no observed effect level was not determined in this study.
DFMO is approved for the treatment of T. brucei and, based on its ability to inhibit cell proliferation, is being further evaluated clinically in cancer treatment and prevention trials (Luk, 1992) . These trials have identified the doselimiting toxicities to be nausea and gastrointestinal upset, loss of hearing acuity, and thrombocytopenia (Abeloff el ai, 1984; Loprinziera/., 1989; Meyskense/a/., 1992) . The reversible toxicities occurred at dosages by oral and intravenous routes as high as 12 g/m 2 /day (approximately 300 mg/ kg) and ototoxicity occurred at dosages as low as 1 g/m 2 /day (approximately 26 mg/kg). While in some instances these effects were noted in chemotherapeutic trials where the patients had received other treatments as well (Paulson et ai, 1992) , in other studies patients who had received no prior chemotherapy were tested (Ajani et ai, 1990) . The use of DFMO in a chemopreventive setting would clearly require the demonstration of efficacy with minimal, acceptable, reversible side effects.
From the animal studies reported here, the dermatological effects of alopecia, scabs and abrasions, dermatitis, hyperkeratosis, and conjunctivitis have not been reported in human clinical trials. The nausea and gastrointestinal upset reported in clinical trials may be correlated to the glandular inflammation of the rat stomach and to the cystic intestinal crypts in the dogs which were observed microscopically. Elevations in human liver enzyme levels, which might correlate to the liver necrosis seen microscopically in the higher male rat dosages, have not been identified. In regards to human thrombocytopenia, the platelet counts were actually increased in the rats treated with 1600 and 800 mg/kg DFMO, whereas, in the dog study at lower dosages, the platelets were not affected. The slight decreases seen in the erythroid parameters in both studies and the slight increase seen in the dog prothrombin time were not of sufficient magnitude to be considered biologically signifi- cant. However, additional measurements of platelet count, prothrombin time, activated partial thromboplastin time, and fibrinogen are being performed in ongoing preclinical studies in both rats and dogs.
Ototoxicity, which would be unlikely to be identified in routine animal toxicity testing, has been shown to occur at multiple frequencies in humans (Croghan el ai, 1991) and an animal model has been studied (Jansen el ai, 1989) . When DFMO was administered to guinea pigs for 12 weeks, histologic examination of the organ of Corti revealed that DFMO caused a loss of hair cells, which was greater among the inner cells than the outer cells (Salzer et aJ., 1990) . In an ongoing preclinical study in dogs the electrophysiological brainstem-evoked auditory response, as well as the histopathology of the brain auditory nuclei and the surface morphology of the inner ear, is being examined. Whether the hearing changes correlate with total accumulated dose or peak blood levels is not yet clear but this would impact the use of DFMO in a chemopreventive setting.
In numerous animal tumor models, which use a large initiating dose of carcinogen, approximately 200 mg DFMO/kg body wt has shown efficacy in the reduction of tumor incidence and multiplicity. These models help identify efficacious agents but the dosages cannot be directly extrapolated to human settings. Chemopreventive efficacy must be demonstrated in humans at dosages below those showing the reversible but potentially serious toxicities described above. Since DFMO in humans is rapidly absorbed and eliminated (C,^ and l{ of 3-4 hr) (Haegele et ai, 1981; Meyskens et ai, 1992) and since ODC has a rapid turnover (t\ about 10-20 min) (Luk and Casero, 1987) , efficacy at very low, nontoxic steady-state levels may be required for some target sites, such as breast, cervix, or prostate. However, since DFMO has an oral bioavailability of 54-58% and is eliminated unchanged primarily by the kidneys (>86%) (Haegele etai, 1981) , colon and bladder are logical target organs. The measurement of polyamine levels and of the inhibition of omithine decarboxylase in target tissues, in conjunction with other biomarkers of dysplasia and in relation to DFMO blood levels, are being undertaken. Several phase I studies are in progress. Patients receiving 0.75 g/m 2 (approximately 19 mg/kg) showed significantly reduced polyamine levels in rectal mucosal biopsy samples (Meyskens et ai, 1992) . At dosages as low as 0.5 g/m 2 (approximately 13 mg/kg) significantly reduced (50% or more) TPA-induced ODC activity in skin biopsy samples was measured and limited, acceptable ototoxicity was experienced after 10 months of treatment (Love et al., 1993) . Decreases in urinary putrescine and spermidine levels were measured in 12 of 19 study subjects after 1 month of treatment with 200 mg/m 2 DFMO or approximately 5 mg/kg (Creaven et ai, 1993; Pendyala et ai, 1993) . Thus, it appears likely that an efficacious dosage with minimal, acceptable toxicity will be defined. In addition, administration of DFMO in combination with other potential chemopreventive agents is being investigated, currently in animal models and in combination with piroxicam in a clinical phase I study.
In the continuum of neoplastic epithelial cell overgrowth, mechanistic opportunities exist for chemopreventive intervention to block carcinogen precursor activation or activated carcinogen binding, to facilitate detoxification by phase II conjugation or free radical quenching, and to suppress neoplastic clonal proliferation (Boone et ai, 1992; Wattenberg, 1985) . The morphological identification of premalignant lesions and the epidemiological knowledge of the natural history of their progression to cancer in numerous organs provide opportunities for observable chemopreventive intervention to suppress proliferation and retard or eliminate the progression to cancer. In the category of proliferation inhibitors, DFMO is a good candidate chemopreventive drug for further clinical development.
